Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 9, Issue 2


Volume 10 (2015)

Interaction between Levothyroxine and Phenprocoumon: a case report

Walderez Gaeti
  • Department of Pharmacology and Therapeutics, State University of Maringa, Avenue Colombo 5790, 87020-290, Maringá, PR, Brazil
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Paulo Obreli-Neto
  • Department of Pharmacology and Therapeutics, State University of Maringa, Avenue Colombo 5790, 87020-290, Maringá, PR, Brazil
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Roberto Cuman
  • Department of Pharmacology and Therapeutics, State University of Maringa, Avenue Colombo 5790, 87020-290, Maringá, PR, Brazil
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-13 | DOI: https://doi.org/10.2478/s11536-013-0260-8


Several case reports have associated the combined use of thyroid drugs and oral anticoagulants, like coumarin, with overanticoagulation. However, this effect has never been described for phenprocoumon, a coumarin derivate that is widely prescribed in continental European countries and in Latin America. We describe a 62-year-old female who had an unexpectedly labile anticoagulation profile when levothyroxine (Puran T4®) was added to her drug therapy regimen, which included phenprocoumon (Marcoumar®). This resulted in an elevated international normalized ratio (INR) that was unrecordable and bleeding (macroscopic hematuria) that required hospitalization and treatment with vitamin K. The patient had been taking phenprocoumon for almost ten years for systemic embolism prophylaxis because of her history of mechanical bileaflet mitral valve prosthesis. One month before the events described, the patient was prescribed sodium levothyroxine (50 mcg daily) to treat hypothyroidism (TSH = 40 µU/mL; reference range, 0.40–4.0 µU/mL). Approximately 3 weeks prior to initiation of levothyroxine treatment, her INR was 2.8. A drug interaction was therefore suspected. The Horn Drug Interaction Probability Scale (DIPS) indicated a probable interaction between oral phenprocoumon and levothyroxine in this case. Clinicians should be aware that levothyroxine may interact with oral phenprocoumon, resulting in overanticoagulation.

Keywords: Drug-drug interaction; Levothyroxine; Phenprocoumon; Overanticoagulation; Oral anticoagulants

  • [1] Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002;117:940–946 http://dx.doi.org/10.1046/j.1365-2141.2002.03493.xCrossrefGoogle Scholar

  • [2] Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S–198S http://dx.doi.org/10.1378/chest.08-0670CrossrefGoogle Scholar

  • [3] Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100:1052–1057 Web of ScienceGoogle Scholar

  • [4] Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66:253–260 http://dx.doi.org/10.1007/s00228-009-0768-7Web of ScienceCrossrefGoogle Scholar

  • [5] Leiria TL, Pellanda L, Miglioranza MH, Sant’anna RT, Becker LS, Magalhães E, et al. Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol 2010;94:41–45 http://dx.doi.org/10.1590/S0066-782X2010000100008Web of ScienceCrossrefGoogle Scholar

  • [6] Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S–21S http://dx.doi.org/10.1378/chest.119.1_suppl.8SCrossrefGoogle Scholar

  • [7] Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004;60:173–182 http://dx.doi.org/10.1007/s00228-004-0740-5CrossrefGoogle Scholar

  • [8] Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227–1246 http://dx.doi.org/10.2165/00003088-200544120-00003CrossrefGoogle Scholar

  • [9] Gavronski M, Hartikainen S, Zharkivsky A. Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharmacy Practice 2012;10:9–16 PubMedGoogle Scholar

  • [10] Brunton L, Parker K, Blumenthal D, Buxton I. Goodman & Gilman. Manual of Pharmacology and Therapeutics. New York: The McGraw-Hill Companies, 2008 Google Scholar

  • [11] British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Publishing Group, 2009 Google Scholar

  • [12] Drugs.com. Drug interactions between coumadin and levothyroxine from Drugs.com. Available from: http://www.drugs.com/drug-interactions/coumadin-with-levothyroxine-2311-1529-1463-0.html. Accessed: 2011 October Google Scholar

  • [13] Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674–680 http://dx.doi.org/10.1345/aph.1H423CrossrefWeb of ScienceGoogle Scholar

  • [14] Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994;10:381–394 http://dx.doi.org/10.2165/00002018-199410050-00003CrossrefGoogle Scholar

  • [15] Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med. 1962;266:76–79 http://dx.doi.org/10.1056/NEJM196201112660205CrossrefGoogle Scholar

  • [16] Bubber P, Bubber N, Bansal DD. Effect of thyroxine on plasminogen activator and inhibitor activity in rat. Indian J Exp Biol 2009;47:147–150 Google Scholar

  • [17] Negrev N, Tashev R, Radev R, Anogeianaki A, Ivanova M. Hormones of hypothalamic-pituitarythyroid axis are significant regulators of synthesis and secretion of vitamin K-dependent plasma coagulation factors. J Biol Regul Homeost Agents 2011;25:21–26 Google Scholar

  • [18] Walters MB. The relationship between thyroid function and anticoagulant therapy. Am J Cardiol 1963;11:112–114 http://dx.doi.org/10.1016/0002-9149(63)90043-2CrossrefGoogle Scholar

  • [19] Food and Drug Administration. Unithroid (levothyroxine sodium tablets, USP). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21210lbl.pdf. Accessed: 2011 October Google Scholar

  • [20] Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30:416–444 http://dx.doi.org/10.2165/00003088-199630060-00002CrossrefGoogle Scholar

About the article

Published Online: 2014-02-13

Published in Print: 2014-04-01

Citation Information: Open Medicine, Volume 9, Issue 2, Pages 231–234, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0260-8.

Export Citation

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Reactions Weekly, 2014, Volume 1495, Number 1, Page 31

Comments (0)

Please log in or register to comment.
Log in